Research · Sep 3, 2026
[SMMT] Summit Therapeutics Thesis 2026: Ivonescimab Lung Cancer Phase 3 Drives PD-L1 Bispecific Disruption
Summit Therapeutics Inc. (NASDAQ: SMMT) FY2025 revenue ~$5-15M (+0-200%) with adj. EPS ~-$0.85 to -$0.65 reflecting selected continued post-2024 selected various Phase 3 ivonescimab clinical-stage development (selected primary HARMONi NSCLC Phase 3 + selected various HARMONi-3 first-line NSCLC Phase 3 + selected various HARMONi-2 NSCLC + selected various HARMONi-6 + selected various ivonescimab pipeline) + selected continued post-2024 ~$650-750M aggregate cash + investments balance + selected post-2022 ~$500M aggregate Akeso Inc. (Hong Kong: 9926) ~$5B+ aggregate Greater China outside ivonescimab license under continued Co-CEO Robert Duggan + Co-CEO Maky Zanganeh since April 2020 (~5-year tenure as Summit Therapeutics Co-CEOs). One of the world's leading clinical-stage biotechnology companies focused on PD-1/L1 + VEGF bispecific antibody ivonescimab development. Founded 2003 as Summit Corporation in Oxford UK; selected post-2015 NASDAQ listing IPO; selected post-April 2020 Robert Duggan + Maky Zanganeh Co-CEO appointment; selected post-December 2022 ~$500M aggregate Akeso Inc. ivonescimab outside Greater China licensing; selected post-September 2024 HARMONi-2 NSCLC Phase 3 first-line readout (China; positive). Headquartered in Menlo Park California; ~150+ employees globally with ~$5-15M revenue. One primary clinical-stage segment: Ivonescimab Phase 3 + Pipeline (~100% ~$5-15M). Geographic mix: US ~70-80% + selected various international + OECD countries ~20-30%. Pipeline mix: HARMONi (~30%), HARMONi-3 (~30%), HARMONi-2 (~20%), HARMONi-6 + early-stage (~20%). Ivonescimab Phase 3 + PD-L1 Bispecific franchise: selected continued post-2024 selected various HARMONi NSCLC Phase 3 + HARMONi-3 first-line NSCLC Phase 3 + HARMONi-2 NSCLC Phase 3 + HARMONi-6 + selected various early-stage pipeline; ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market; selected potential 2026-2027 first FDA approval. Akeso licensing + outside Greater China rights: post-December 2022 ~$500M aggregate Akeso ivonescimab outside Greater China licensing; ~$5B+ aggregate combined upfront + milestones + tiered royalties. Co-CEOs Robert Duggan + Maky Zanganeh since April 2020 (~5-year tenure); CFO Sandeep Sandhu. Capital + cash position: ~$650-750M aggregate cash + investments balance; ~$0M aggregate net debt position; selected post-2020 ~$200M+ aggregate Robert Duggan + Maky Zanganeh + selected various Summit Therapeutics personal investment; selected pathway to first commercialization FY2026-2028; investment-grade pathway pre-revenue inflection. FY2026 thesis: Ivonescimab Phase 3 + PD-L1 Bispecific franchise + Akeso licensing + outside Greater China rights + ~$60B+ aggregate global PD-1/L1 + VEGF bispecific antibody addressable market + ~$650-750M aggregate cash + investments balance + ~$0M aggregate net debt + selected potential post-2024 FDA filing + selected potential 2026-2027 first FDA approval. Risks: Phase 3 ivonescimab Phase 3 readouts risk, Merck Keytruda + AstraZeneca + Roche + BMS competition, FDA filing pathway uncertainty, Akeso licensing terms execution, continued cash burn.